A closer look at menopause and VMS
| Subgroup | PADCEV + pembrolizumab mOS, Months (Events/N) |
Chemotherapy mOS, Months (Events/N) |
Hazard Ratio (95% CI) | |
|---|---|---|---|---|
| Overall | 31.5 (133/442) | 16.1 (226/444) | 0.47 (0.38, 0.58) | |
| Age | ||||
| <65 years | NR (39/144) | 19.7 (58/135) | 0.46 (0.30, 0.71) | |
| ≥65 years | 31.5 (94/298) | 14.6 (168/309) | 0.48 (0.38, 0.63) | |
| Region | ||||
| North America | 25.6 (40/103) | 21.2 (42/85) | 0.71 (0.44, 1.12) | |
| Europe | NE (56/172) | 13.9 (110/197) | 0.40 (0.28, 0.56) | |
| Rest of world | NE (37/167) | 16.4 (74/162) | 0.41 (0.27, 0.61) | |
During the menopausal transition, many women experience sleep disturbances, changes in mood and cognitive performance, migraine, and Vasomotor Symptoms (VMS), also known as hot flushes and night sweats. They also undergo physical changes, which can continue long into postmenopause, including changes in body shape, osteoporosis, increased risk of cardiovascular events, ageing of hair and skin, and vulvovaginal atrophy.1
Vasomotor Symptoms are the most commonly reported symptoms of the menopausal transition. Up to 80% of women are affected by VMS during the menopausal transition.2
VMS arise from heightened neuronal activity in the hypothalamus VMS & Menopause. This leads to hypertrophy of KNDy neurons and altered activity in the temperature control centre. The resulting VMS include the uncomfortable feeling of heat and sweating, which can disrupt women’s daily lives.1-5
Link Style :-
Font size of Text as 'Step 0' and Icon with Size as 'S'
Font size of Text as 'Step-1' and Icon with Size as 'XS'
Font size of Text as 'Step-2' and Icon with Size as '2XS'
Icon Style :-
Icon with Size as 'S'
Icon with Size as 'M'
Icon with Size as 'L'
Secondary Icon
Use of Myrbetriq
MYRBETRIQ® (mirabegron extended-release tablets) is a prescription medicine for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage.
Do not take MYRBETRIQ if you are allergic to mirabegron or any ingredients in MYRBETRIQ.
MYRBETRIQ may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. You and your doctor should check your blood pressure while you are taking MYRBETRIQ. Call your doctor if you have increased blood pressure.
MYRBETRIQ may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream. MYRBETRIQ may cause an allergic reaction with swelling of the face, lips, throat or tongue with or without difficulty breathing. Stop using MYRBETRIQ and go to the nearest hospital emergency room right away.
Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines especially thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®) or solifenacin succinate (VESIcare®). MYRBETRIQ may affect the way other medicines work, and other medicines may affect how MYRBETRIQ works.
Before taking MYRBETRIQ, tell your doctor about all of your medical conditions, including if you have liver or kidney problems.
The most common side effects of MYRBETRIQ include high blood pressure, pain or swelling of the nose or throat (nasopharyngitis), urinary tract infection, and headache.
For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information for MYRBETRIQ® (mirabegron extended‑release tablets).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Use of Myrbetriq
MYRBETRIQ® (mirabegron extended-release tablets) is a prescription medicine for adults used to treat overactive bladder (OAB) with symptoms of urgency, frequency and leakage.
Do not take MYRBETRIQ if you are allergic to mirabegron or any ingredients in MYRBETRIQ.
MYRBETRIQ may cause your blood pressure to increase or make your blood pressure worse if you have a history of high blood pressure. You and your doctor should check your blood pressure while you are taking MYRBETRIQ. Call your doctor if you have increased blood pressure.
MYRBETRIQ may increase your chances of not being able to empty your bladder. Tell your doctor right away if you have trouble emptying your bladder or you have a weak urine stream. MYRBETRIQ may cause an allergic reaction with swelling of the face, lips, throat or tongue with or without difficulty breathing. Stop using MYRBETRIQ and go to the nearest hospital emergency room right away.
Tell your doctor about all the medicines you take including medications for overactive bladder or other medicines especially thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®) or solifenacin succinate (VESIcare®). MYRBETRIQ may affect the way other medicines work, and other medicines may affect how MYRBETRIQ works.
Before taking MYRBETRIQ, tell your doctor about all of your medical conditions, including if you have liver or kidney problems.
The most common side effects of MYRBETRIQ include high blood pressure, pain or swelling of the nose or throat (nasopharyngitis), urinary tract infection, and headache.
For further information, please talk to your healthcare professional and see accompanying Patient Product Information and complete Prescribing Information for MYRBETRIQ® (mirabegron extended‑release tablets).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Getting Started
OAB Resources